1 Recommendations

1 Recommendations

1.1 Blinatumomab is recommended within its marketing authorisation as an option for treating Philadelphia-chromosome-negative relapsed or refractory precursor B-cell acute lymphoblastic leukaemia in adults, only if the company provides it with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)